How J&J’s deal for Legend’s anti-BCMA CAR will shape its cell therapy strategy
Johnson & Johnson’s deal with Legend Biotech will net the pharma both an anti-BCMA CAR T therapy and a partner to help shape its cell therapy strategy.
J&J chose the Chinese company’s LCAR-B38M as its first chimeric antigen receptor (CAR) T cell product, and as a first step in what is likely to be a measured approach using partnerships to build knowledge and capabilities for optimizing cell therapies for cancer.
On Dec. 21, Janssen announced a licensing collaboration with the Legend Biotech USA Inc. and Legend Biotech Ireland Ltd. subsidiaries of Nanjing-based Genscript Biotech Corp. for LCAR-B38M, a CAR T therapy that targets BCMA (TNF receptor superfamily member 17; TNFRSF17). Legend received $350 million up front and is eligible for undisclosed milestones. Janssen and Legend will share costs